Generated by AI
Champions Oncology, Inc. is a biotechnology research services company focused on oncology drug development. Champions Oncology provides preclinical and clinical specialty testing, translational research, and data-driven software solutions that help pharmaceutical and biotechnology companies evaluate cancer therapies. Its core offerings include proprietary tumor models, in vivo and ex vivo research platforms, biomarker analysis, and the TumorGraft technology platform, which supports more personalized approaches to oncology research. The company also offers Lumin Bioinformatics, a software platform that combines research and clinical data for computational cancer analysis and decision-making support. Champions Oncology serves drug developers, research organizations, and medical professionals through technology-enabled services centered on improving the understanding and development of cancer treatments. Headquartered in Hackensack, New Jersey, Champions Oncology operates as a specialized provider within the broader oncology contract research and life sciences tools market.
WebsiteOne University Plaza
Hackensack, NJ, 07601
United States
The latest articles about CSBR.
On Monday, Champions Oncology (NASDAQ:CSBR) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Champions Oncology (NASDAQ:CSBR) released third-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
On Thursday, Champions Oncology (NASDAQ:CSBR) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Summary of Dec 15's posts. Generated by AI.
No summary yet.
Summary of Dec 17's posts. Generated by AI.
Summary of Sep 12's posts. Generated by AI.
Investors talking about CSBR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.